Literature DB >> 12391234

Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences.

William F Dall'Acqua1, Robert M Woods, E Sally Ward, Susan R Palaszynski, Nita K Patel, Yambasu A Brewah, Herren Wu, Peter A Kiener, Solomon Langermann.   

Abstract

Many biological functions, including control of the homeostasis and maternofetal transfer of serum gamma-globulins, are mediated by the MHC class I-related neonatal FcR (FcRn). A correlation exists in mice between the binding affinity of IgG1/Fc fragments to FcRn at pH 6.0 and their serum t(1/2). To expand this observation, phage display of mutagenized Fc fragments derived from a human IgG1 was used to increase their affinity to both murine and human FcRn. Ten variants were identified that have a higher affinity toward murine and human FcRn at pH 6.0, with DeltaDeltaG (DeltaG(wild type) - DeltaG(mutant)) from 1.0 to 2.0 kcal/mol and from 0.6 to 2.4 kcal/mol, respectively. Those variants exhibit a parallel increase in binding at pH 7.4 to murine, but not human, FcRn. Although not degraded in blood in vitro, accumulated in tissues, nor excreted in urine, their serum concentration in mice is decreased. We propose that higher affinity to FcRn at pH 7.4 adversely affects release into the serum and offsets the benefit of the enhanced binding at pH 6.0.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12391234     DOI: 10.4049/jimmunol.169.9.5171

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  119 in total

1.  Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeys.

Authors:  Amita Datta-Mannan; Derrick R Witcher; Jirong Lu; Victor J Wroblewski
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

2.  Generation and comparative characterization of glycosylated and aglycosylated human IgG1 antibodies.

Authors:  Dmitrij Hristodorov; Rainer Fischer; Hannah Joerissen; Beate Müller-Tiemann; Heiner Apeler; Lars Linden
Journal:  Mol Biotechnol       Date:  2013-03       Impact factor: 2.695

Review 3.  Development of anti-infectives using phage display: biological agents against bacteria, viruses, and parasites.

Authors:  Johnny X Huang; Sharon L Bishop-Hurley; Matthew A Cooper
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

4.  Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys.

Authors:  Patrick M Glassman; Yang Chen; Joseph P Balthasar
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-12       Impact factor: 2.745

5.  pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling.

Authors:  M Jack Borrok; Yanli Wu; Nurten Beyaz; Xiang-Qing Yu; Vaheh Oganesyan; William F Dall'Acqua; Ping Tsui
Journal:  J Biol Chem       Date:  2014-12-23       Impact factor: 5.157

6.  Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor.

Authors:  Jaspreet Singh Jaggi; Jorge A Carrasquillo; Surya V Seshan; Pat Zanzonico; Erik Henke; Andrew Nagel; Jazmin Schwartz; Brad Beattie; Barry J Kappel; Debjit Chattopadhyay; Jing Xiao; George Sgouros; Steven M Larson; David A Scheinberg
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

7.  Cynomolgus and pigtail macaque IgG subclasses: characterization of IGHG genes and computational analysis of IgG/Fc receptor binding affinity.

Authors:  Doan C Nguyen; Rashesh Sanghvi; Franco Scinicariello; Joanna Pulit-Penaloza; Nicole Hill; Roberta Attanasio
Journal:  Immunogenetics       Date:  2014-05-09       Impact factor: 2.846

Review 8.  Targeting FcRn for the modulation of antibody dynamics.

Authors:  E Sally Ward; Siva Charan Devanaboyina; Raimund J Ober
Journal:  Mol Immunol       Date:  2015-03-09       Impact factor: 4.407

9.  Expression of neonatal Fc receptor in the eye.

Authors:  Michael B Powner; Jenny A G McKenzie; Gregory J Christianson; Derry C Roopenian; Marcus Fruttiger
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-19       Impact factor: 4.799

Review 10.  Engineered antibodies for molecular imaging of cancer.

Authors:  Anna M Wu
Journal:  Methods       Date:  2013-10-01       Impact factor: 3.608

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.